Search: onr:"swepub:oai:lup.lub.lu.se:d75dfdfd-10cc-4c8b-bc05-3ed7024bf587" > Danegaptide for pri...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05001naa a2200589 4500 | |
001 | oai:lup.lub.lu.se:d75dfdfd-10cc-4c8b-bc05-3ed7024bf587 | |
003 | SwePub | |
008 | 180717s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/d75dfdfd-10cc-4c8b-bc05-3ed7024bf5872 URI |
024 | 7 | a https://doi.org/10.1136/heartjnl-2017-3127742 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Engstrøm, Thomasu Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,University of Copenhagen4 aut0 (Swepub:lu)th4331en |
245 | 1 0 | a Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients : A phase 2 randomised clinical trial |
264 | c 2018-03-30 | |
264 | 1 | b BMJ,c 2018 |
520 | a Objectives: Reperfusion immediately after reopening of the infarct-related artery in ST-segment elevation myocardial infarction (STEMI) may cause myocardial damage in addition to the ischaemic insult (reperfusion injury). The gap junction modulating peptide danegaptide has in animal models reduced this injury. We evaluated the effect of danegaptide on myocardial salvage in patients with STEMI. Methods: In addition to primary percutaneous coronary intervention in STEMI patients with thrombolysis in myocardial infarction flow 0-1, single vessel disease and ischaemia time less than 6 hours, we tested, in a clinical proof-of-concept study, the therapeutic potential of danegaptide at two-dose levels. Primary outcome was myocardial salvage evaluated by cardiac MRI after 3 months. Results: From November 2013 to August 2015, a total of 585 patients were randomly enrolled in the trial. Imaging criteria were fulfilled for 79 (high dose), 80 (low dose) and 84 (placebo) patients eligible for the per-protocol analysis. Danegaptide did not affect the myocardial salvage index (danegaptide high (63.9±14.9), danegaptide low (65.6±15.6) and control (66.7±11.7), P=0.40), final infarct size (danegaptide high (19.6±11.4 g), danegaptide low (18.6±9.6 g) and control (21.4±15.0 g), P=0.88) or left ventricular ejection fraction (danegaptide high (53.9%±9.5%), danegaptide low (52.7%±10.3%) and control (52.1%±10.9%), P=0.64). There was no difference between groups with regard to clinical outcome. Conclusions: Administration of danegaptide to patients with STEMI did not improve myocardial salvage. Trial registration number: NCT01977755; Pre-results. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a acute myocardial infarction | |
653 | a cardiac magnetic resonance (cmr) imaging | |
653 | a percutaneous coronary intervention | |
700 | 1 | a Nepper-Christensen, Larsu University of Copenhagen4 aut |
700 | 1 | a Helqvist, Steffenu University of Copenhagen4 aut |
700 | 1 | a Kløvgaard, Leneu University of Copenhagen4 aut |
700 | 1 | a Holmvang, Leneu University of Copenhagen4 aut |
700 | 1 | a Jørgensen, Eriku University of Copenhagen4 aut |
700 | 1 | a Pedersen, Frantsu University of Copenhagen4 aut |
700 | 1 | a Saunamaki, Kariu University of Copenhagen4 aut |
700 | 1 | a Tilsted, Hans Henriku University of Copenhagen4 aut |
700 | 1 | a Steensberg, Adamu Zealand Pharma A/S4 aut |
700 | 1 | a Fabricius, Sørenu Zealand Pharma A/S4 aut |
700 | 1 | a Mouritzen, Ulriku Zealand Pharma A/S4 aut |
700 | 1 | a Vejlstrup, Nielsu University of Copenhagen4 aut |
700 | 1 | a Ahtarovski, Kiril A.u University of Copenhagen4 aut |
700 | 1 | a Göransson, Christofferu University of Copenhagen4 aut |
700 | 1 | a Bertelsen, Littenu University of Copenhagen4 aut |
700 | 1 | a Kyhl, Kasperu University of Copenhagen4 aut |
700 | 1 | a Olivecrona, Göranu Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kard-gol |
700 | 1 | a Kelbæk, Henningu Zealand University Hospital4 aut |
700 | 1 | a Lassen, Jens Flenstedu University of Copenhagen4 aut |
700 | 1 | a Køber, Larsu University of Copenhagen4 aut |
700 | 1 | a Lønborg, Jacobu University of Copenhagen4 aut |
710 | 2 | a Kardiologib Sektion II4 org |
773 | 0 | t Heartd : BMJg 104:19, s. 1593-1599q 104:19<1593-1599x 1355-6037x 1468-201X |
856 | 4 | u http://dx.doi.org/10.1136/heartjnl-2017-312774y FULLTEXT |
856 | 4 | u https://heart.bmj.com/content/heartjnl/104/19/1593.full.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/d75dfdfd-10cc-4c8b-bc05-3ed7024bf587 |
856 | 4 8 | u https://doi.org/10.1136/heartjnl-2017-312774 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view